An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans

Clinical and Vaccine Immunology

Volumn 21, Issue 8, 2014, Pages 1153-1163

  Krammer, Florian ^a   Jul Larsen, Åsne ^b   Margine, Irina ^a   Hirsh, Ariana ^a   Sjursen, Haakon ^b,c   Zambon, Maria ^d   Cox, Rebecca J ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

H7N1 INFLUENZA VIRUS VACCINE; INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; HEMAGGLUTININ, AVIAN INFLUENZA A VIRUS; IMMUNOGLOBULIN G; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; VIRUS ANTIGEN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSS REACTION; DRUG DOSE ESCALATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INFECTION PREVENTION; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA VACCINATION; MOUSE; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS; VIRUS IMMUNITY; VIRUS REPLICATION; VIRUS STRAIN; YOUNG ADULT; ANIMAL; ANTIBODY AFFINITY; DOG; IMMUNOLOGY; INFLUENZA A VIRUS (H7N1); INFLUENZA A VIRUS (H7N9); MDCK CELL LINE; VACCINATION;

ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; ANTIGENS, VIRAL; CROSS REACTIONS; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H7N1 SUBTYPE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; MADIN DARBY CANINE KIDNEY CELLS; MICE; VACCINATION; YOUNG ADULT;

EID: 84906670725     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00272-14     Document Type: Article

References (52)

1. Fouchier RA, Schneeberger PM, Rozendaal FW, Broekman JM, Kemink SA, Munster V, Kuiken T, Rimmelzwaan GF, Schutten M, Van Doornum GJ, Koch G, Bosman A, Koopmans M, Osterhaus AD. 2004. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. U. S. A. 101:1356-1361. http://dx.doi.org/10. 1073/pnas.0308352100. (Pubitemid 38182693)
2. Tweed SA, Skowronski DM, David ST, Larder A, Petric M, Lees W, Li Y, Katz J, Krajden M, Tellier R, Halpert C, Hirst M, Astell C, Lawrence D, Mak A. 2004. Human illness from avian influenza H7N3, British Columbia. Emerg. Infect. Dis. 10:2196-2199. http://dx.doi.org/10.3201/eid1012.040961. (Pubitemid 39587346)
3. Centers for Disease Control and Prevention. 2012. Notes from the field: highly pathogenic avian influenza A (H7N3) virus infection in two poultry workers - Jalisco, Mexico, July 2012.MMWRMorb. Mortal. Wkly. Rep. 61: 726-727. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6136a4.htm.
4. Cox RJ, Major D, Hauge S, Madhun AS, Brokstad KA, Kuhne M, Smith J, Vogel FR, Zambon M, Haaheim LR, Wood J. 2009. A cell-based H7N1 split influenza virion vaccine confers protection in mouse and ferret challenge models. Influenza Other Respir. Viruses 3:107-117. http://dx.doi.org/10.1111/j.1750- 2659.2009.00082.x.
5. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, Höschler K, Saville M, Vogel FR, Barclay W, Donatelli I, Zambon M, Wood J, Haaheim LR. 2009. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 27:1889-1897. http://dx.doi.org/10.1016/j.vaccine.2009.01.116.
6. Couch RB, Patel SM, Wade-Bowers CL, Niño D. 2012. A randomized clinical trial of an inactivated avian influenzaA(H7N7) vaccine. PLoS One 7(12):e49704. http://dx.doi.org/10.1371/journal.pone.0049704.
7. Joseph T, McAuliffe J, Lu B, Vogel L, Swayne D, Jin H, Kemble G, Subbarao K. 2008. A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology 378:123-132. http://dx.doi.org/10.1016/j.virol.2008.05.021.
8. Min JY, Vogel L, Matsuoka Y, Lu B, Swayne D, Jin H, Kemble G, Subbarao K. 2010. A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J. Virol. 84:11950-11960. http://dx.doi.org/10.1128/JVI.01305-10.
9. Talaat KR, Karron RA, Callahan KA, Luke CJ, DiLorenzo SC, Chen GL, Lamirande EW, Jin H, Coelingh KL, Murphy BR, Kemble G, Subbarao K. 2009. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 27:3744-3753. http://dx.doi.org/10. 1016/j.vaccine.2009.03.082.
10. Rudenko L, Kiseleva I, Naykhin AN, Erofeeva M, Stukova M, Donina S, Petukhova G, Pisareva M, Krivitskaya V, Grudinin M, Buzitskaya Z, Isakova-Sivak I, Kuznetsova S, Larionova N, Desheva J, Dubrovina I, Nikiforova A, Victor JC, Neuzil K, Flores J, Tsvetnitsky V, Kiselev O. 2014. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. PLoS One 9(2):e87962. http://dx.doi.org/10.1371/journal. pone.0087962.
11. Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, Chen J, Jie Z, Qiu H, Xu K, Xu X, Lu H, Zhu W, Gao Z, Xiang N, Shen Y, He Z, Gu Y, Zhang Z, Yang Y, Zhao X, Zhou L, Li X, Zou S, Zhang Y, Yang L, Guo J, Dong J, Li Q, Dong L, Zhu Y, Bai T, Wang S, Hao P, Yang W, Han J, Yu H, Li D, Gao GF, Wu G, Wang Y, Yuan Z, Shu Y. 2013. Human infection with a novel avian-origin influenza A (H7N9) virus. N. Engl. J. Med. 368:1888-1897. http://dx.doi.org/10.1056/NEJMoa1304459.
12. Anonymous. 2014. Map and epidemiological curve of confirmed human cases of avian influenza A(H7N9). World Health Organization, Geneva, Switzerland. http://www.who.int/influenza/human-animal-interface/influenza-h7n9/Data-Reports/ en/.
13. Hai R, Schmolke M, Leyva-Grado VH, Thangavel RR, Margine I, Jaffe EL, Krammer F, Solórzano A, García-Sastre A, Palese P, Bouvier NM. 2013. Influenza A(H7N9) virus gains neuraminidase inhibitor resistance without loss of in vivo virulence or transmissibility. Nat. Commun. 4:2854. http://dx.doi.org/10.1038/ncomms3854.
14. Watanabe T, Kiso M, Fukuyama S, Nakajima N, Imai M, Yamada S, Murakami S, Yamayoshi S, Iwatsuki-Horimoto K, Sakoda Y, Takashita E, McBride R, Noda T, Hatta M, Imai H, Zhao D, Kishida N, Shirakura M, de Vries RP, Shichinohe S, Okamatsu M, Tamura T, Tomita Y, Fujimoto N, Goto K, Katsura H, Kawakami E, Ishikawa I, Watanabe S, Ito M, Sakai-Tagawa Y, Sugita Y, Uraki R, Yamaji R, Eisfeld AJ, Zhong G, Fan S, Ping J, Maher EA, Hanson A, Uchida Y, Saito T, Ozawa M, Neumann G, Kida H, Odagiri T, Paulson JC, Hasegawa H, Tashiro M, Kawaoka Y. 2013. Characterization of H7N9 influenza A viruses isolated from humans. Nature 501:551-555. http://dx.doi.org/10.1038/nature12392.
15. Belser JA, Gustin KM, Pearce MB, Maines TR, Zeng H, Pappas C, Sun X, Carney PJ, Villanueva JM, Stevens J, Katz JM, Tumpey TM. 2013. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 501: 556-559. http://dx.doi.org/10.1038/nature12391.
16. Zhu H, Wang D, Kelvin DJ, Li L, Zheng Z, Yoon SW, Wong SS, Farooqui A, Wang J, Banner D, Chen R, Zheng R, Zhou J, Zhang Y, Hong W, Dong W, Cai Q, Roehrl MH, Huang SS, Kelvin AA, Yao T, Zhou B, Chen X, Leung GM, Poon LL, Webster RG, Webby RJ, Peiris JS, Guan Y, Shu Y. 2013. Infectivity, transmission, and pathology of human H7N9 influenza in ferrets and pigs. Science 341:183-186. http://dx.doi.org/10.1126/science.1239844.
17. Ramos I, Krammer F, Hai R, Aguilera D, Bernal-Rubio D, Steel J, García-Sastre A, Fernandez-Sesma A. 2013. H7N9 influenza viruses interact preferentially with α2,3-linked sialic acids and bind weakly to α2,6-linked sialic acids. J. Gen. Virol. 94:2417-2423. http://dx.doi.org/10.1099/vir.0.056184-0.
18. Xu R, de Vries RP, Zhu X, Nycholat CM, McBride R, Yu W, Paulson JC, Wilson IA. 2013. Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science 342:1230-1235. http://dx.doi.org/10.1126/ science.1243761.
19. Hu Y, Lu S, Song Z, Wang W, Hao P, Li J, Zhang X, Yen HL, Shi B, Li T, Guan W, Xu L, Liu Y, Wang S, Tian D, Zhu Z, He J, Huang K, Chen H, Zheng L, Li X, Ping J, Kang B, Xi X, Zha L, Li Y, Zhang Z, Peiris M, Yuan Z. 2013. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 381:2273-2279. http://dx.doi.org/10.1016/S0140-6736(13)61125- 3.
20. Terajima M, Cruz J, Co MD, Lee JH, Kaur K, Wrammert J, Wilson PC, Ennis FA. 2011. Complement-dependent lysis of influenza A virus-infected cells by broadly cross-reactive human monoclonal antibodies. J. Virol. 85:13463-13467. http://dx.doi.org/10.1128/JVI.05193-11.
21. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. 2013. Antibody-dependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J. Virol. 87:5512-5522. http://dx.doi.org/10.1128/JVI.03030-12.
22. Jegaskanda S, Job ER, Kramski M, Laurie K, Isitman G, de Rose R, Winnall WR, Stratov I, Brooks AG, Reading PC, Kent SJ. 2013. Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J. Immunol. 190:1837-1848. http://dx.doi.org/10.4049/jimmunol.1201574.
23. DiLillo DJ, Tan GS, Palese P, Ravetch JV. 2014. Broadly neutralizing hemagglutinin stalk-specific antibodies require Fc R interactions for protection against influenza virus in vivo. Nat. Med. 20:143-151. http://dx.doi.org/10. 1038/nm.3443.
24. Krammer F, Schinko T, Palmberger D, Tauer C, Messner P, Grabherr R. 2010. Trichoplusia ni cells (High Five) are highly efficient for the production of influenza A virus-like particles: a comparison of two insect cell lines as production platforms for influenza vaccines. Mol. Biotechnol. 45:226-234. http://dx.doi.org/10.1007/s12033-010-9268-3.
25. Klausberger M, Wilde M, Palmberger D, Hai R, Albrecht RA, Margine I, Hirsh A, García-Sastre A, Grabherr R, Krammer F. 2014. One-shot vaccination with an insect cell-derived low-dose influenza A H7 virus-like particle preparation protects mice against H7N9 challenge. Vaccine 32:355-362. http://dx.doi.org/10.1016/j.vaccine.2013.11.036.
26. Krammer F, Albrecht RA, Tan GS, Margine I, Hai R, Schmolke M, Runstadler J, Andrews SF, Wilson PC, Cox RJ, Treanor JJ, García-Sastre A, Palese P. 2014. Divergent H7 immunogens offer protection from H7N9 challenge. J. Virol. 88:3976-3985. http://dx.doi.org/10.1128/JVI.03095-13.
27. Goff PH, Krammer F, Hai R, Seibert CW, Margine I, García-Sastre A, Palese P. 2013. Induction of cross-reactive antibodies to novel H7N9 influenza virus by recombinant Newcastle disease virus expressing a North American lineage H7 subtype hemagglutinin. J. Virol. 87:8235-8240. http://dx.doi.org/10.1128/ JVI.01085-13.
28. Margine I, Martinez-Gil L, Chou YY, Krammer F. 2012. Residual baculovirus in insect cell-derived influenza virus-like particle preparations enhances immunogenicity. PLoS One 7(12):e51559. http://dx.doi.org/10.1371/journal.pone. 0051559.
29. Krammer F, Margine I, Tan GS, Pica N, Krause JC, Palese P. 2012. A carboxy-terminal trimerization domain stabilizes conformational epitopes on the stalk domain of soluble recombinant hemagglutinin substrates. PLoS One 7(8):e43603. http://dx.doi.org/10.1371/journal.pone.0043603.
30. Margine I, Palese P, Krammer F. 2013. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 Influenza virus using the baculovirus expression system. J. Vis. Exp. 81:e51112. http://dx.doi.org/10.3791/51112.
31. Hai R, Krammer F, Tan GS, Pica N, Eggink D, Maamary J, Margine I, Albrecht RA, Palese P. 2012. Influenza viruses expressing chimeric hemagglutinins: globular head and stalk domains derived from different subtypes. J. Virol. 86:5774-5781. http://dx.doi.org/10.1128/JVI.00137-12.
32. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, Lim W, Fukuda K, Cox NJ, Katz JM. 1999. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J. Clin. Microbiol. 37:937-943. (Pubitemid 29140593)
33. Miller MS, Gardner TJ, Krammer F, Aguado LC, Tortorella D, Basler CF, Palese P. 2013. Neutralizing antibodies against previously encountered influenza virus strains increase over time: a longitudinal analysis. Sci. Transl. Med. 5(198):198ra107. http://dx.doi.org/10.1126/scitranslmed.3006637.
34. Gerhard W, Yewdell J, Frankel ME, Webster R. 1981. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature 290:713-717. http://dx.doi.org/10.1038/290713a0. (Pubitemid 11068963)
35. Couch RB, Decker WK, Utama B, Atmar RL, Niño D, Feng JQ, Halpert MM, Air GM. 2012. Evaluations for in vitro correlates of immunogenicity of inactivated influenza a H5, H7 and H9 vaccines in humans. PLoS One 7(12):e50830. http://dx.doi.org/10.1371/journal.pone.0050830.
36. Wei SH, Yang JR, Wu HS, Chang MC, Lin JS, Lin CY, Liu YL, Lo YC, Yang CH, Chuang JH, Lin MC, Chung WC, Liao CH, Lee MS, Huang WT, Chen PJ, Liu MT, Chang FY. 2013. Human infection with avian influenza A H6N1 virus: an epidemiological analysis. Lancet Respir. Med. 1:771-778. http://dx.doi.org/10.1016/S2213- 2600(13)70221-2.
37. To KK, Tsang AK, Chan JF, Cheng VC, Chen H, Yuen KY. 2014. Emergence in China of human disease due to avian influenza A(H10N8) - cause for concern? J. Infect. 68:205-215. http://dx.doi.org/10.1016/j.jinf.2013.12.014.
38. Wrammert J, Smith K, Miller J, Langley WA, Kokko K, Larsen C, Zheng NY, Mays I, Garman L, Helms C, James J, Air GM, Capra JD, Ahmed R, Wilson PC. 2008. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453:667-671. http://dx.doi.org/10.1038/nature06890. (Pubitemid 351769295)
39. Moody MA, Zhang R, Walter EB, Woods CW, Ginsburg GS, McClain MT, Denny TN, Chen X, Munshaw S, Marshall DJ, Whitesides JF, Drinker MS, Amos JD, Gurley TC, Eudailey JA, Foulger A, DeRosa KR, Parks R, Meyerhoff RR, Yu JS, Kozink DM, Barefoot BE, Ramsburg EA, Khurana S, Golding H, Vandergrift NA, Alam SM, Tomaras GD, Kepler TB, Kelsoe G, Liao HX, Haynes BF. 2011. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS One 6(10):e25797. http://dx.doi.org/10.1371/journal.pone.0025797.
40. Rudenko L, Isakova-Sivak I, Rekstin A. 2014. H7N9: can H7N3 live-attenuated influenza vaccine be used at the early stage of the pandemic? Expert Rev. Vaccines 13:1-4. http://dx.doi.org/10.1586/14760584.2014.864564.
41. Joseph T, McAuliffe J, Lu B, Jin H, Kemble G, Subbarao K. 2007. Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J. Virol. 81:10558-10566. http://dx.doi.org/10.1128/ JVI.00970-07. (Pubitemid 47463329)
42. Margine I, Hai R, Albrecht RA, Obermoser G, Harrod AC, Banchereau J, Palucka K, García-Sastre A, Palese P, Treanor JJ, Krammer F. 2013. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J. Virol. 87:4728-4737. http://dx.doi.org/10. 1128/JVI.03509-12.
43. Krammer F, Pica N, Hai R, Tan GS, Palese P. 2012. Hemagglutinin stalk-reactive antibodies are boosted following sequential infection with seasonal and pandemic H1N1 influenza virus in mice. J. Virol. 86:10302-10307. http://dx.doi.org/10.1128/JVI.01336-12.
44. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R. 2012. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl. Acad. Sci. U. S. A. 109:9047-9052. http://dx.doi.org/10.1073/pnas.1118979109.
45. Wrammert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del Rio C, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193. http://dx.doi.org/10.1084/jem.20101352.
46. Thomson CA, Wang Y, Jackson LM, Olson M, Wang W, Liavonchanka A, Keleta L, Silva V, Diederich S, Jones RB, Gubbay J, Pasick J, Petric M, Jean F, Allen VG, Brown EG, Rini JM, Schrader JW. 2012. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem. Front. Immunol. 3:87. http://dx.doi.org/10.3389/fimmu.2012. 00087.
47. Pica N, Hai R, Krammer F, Wang TT, Maamary J, Eggink D, Tan GS, Krause JC, Moran T, Stein CR, Banach D, Wrammert J, Belshe RB, García-Sastre A, Palese P. 2012. Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. U. S. A. 109:2573-2578. http://dx.doi.org/10.1073/pnas. 1200039109.
48. Sangster MY, Baer J, Santiago FW, Fitzgerald T, Ilyushina NA, Sundararajan A, Henn AD, Krammer F, Yang H, Luke CJ, Zand MS, Wright PF, Treanor JJ, Topham DJ, Subbarao K. 2013. B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccination. Clin. Vaccine Immunol. 20:867-876. http://dx.doi.org/10.1128/CVI.00735-12.
49. Krammer F, Palese P. 2013. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr. Opin. Virol. 3:521-530. http://dx.doi.org/10. 1016/j.coviro.2013.07.007.
50. Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H. 2013. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci. Transl. Med. 5 (200) : 200ra114. http://dx.doi.org/10.1126/scitranslmed.3006366.
51. Krammer F, Cox RJ. 2013. The emergence of H7N9 viruses: a chance to redefine correlates of protection for influenza virus vaccines. Expert Rev. Vaccines 12:1369-1372. http://dx.doi.org/10.1586/14760584.2013.850036.
52. Yang H, Carney PJ, Chang JC, Villanueva JM, Stevens J. 2013. Structural analysis of the hemagglutinin from the recent 2013 H7N9 influenza virus. J. Virol. 87:12433-12446. http://dx.doi.org/10.1128/JVI.01854-13.